Mbx Biosciences Common Stock Performance
| MBX Stock | 40.53 0.38 0.93% |
MBX Biosciences holds a performance score of 23 on a scale of zero to a hundred. The firm secures a Beta (Market Risk) of 0.26, which conveys not very significant fluctuations relative to the market. As returns on the market increase, MBX Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding MBX Biosciences is expected to be smaller as well. Use MBX Biosciences Common semi variance, as well as the relationship between the daily balance of power and price action indicator , to analyze future returns on MBX Biosciences Common.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MBX Biosciences Common are ranked lower than 23 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental drivers, MBX Biosciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.93) | Five Day Return 25.75 | Year To Date Return 32.67 | Ten Year Return 71.37 | All Time Return 71.37 |
1 | Disposition of 182859 shares by Hawryluk P. Kent of MBX Biosciences, at 3.25 subject to Rule 16b-3 | 10/24/2025 |
2 | Form 4 MBX Biosciences, Inc. Insider Trading Activity - Stock Titan | 10/28/2025 |
3 | MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data - Investing.com | 11/20/2025 |
4 | Acquisition by Steven Hoerter of 8000 shares of MBX Biosciences, at 27.08 subject to Rule 16b-3 | 11/21/2025 |
5 | A Look at MBX Biosciences Valuation Following Phase 2 Results and Public Offering Plans | 11/25/2025 |
6 | How Much Upside is Left in MBX Biosciences, Inc. Wall Street Analysts Think 80.6 | 12/01/2025 |
7 | Do MBX Biosciences Phase 2 Win and Cash Raise Strengthen Its Platform Story or Expose Limits | 12/05/2025 |
8 | Resolute Capital Asset Partners LLC Acquires New Position in MBX Biosciences, Inc. MBX | 12/09/2025 |
9 | MBX Biosciences Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation | 12/16/2025 |
10 | Is UBSs Canvuparatide Focus Altering The Investment Case For MBX Biosciences | 01/09/2026 |
| Begin Period Cash Flow | 30.5 M | |
| Total Cashflows From Investing Activities | -160.6 M |
MBX Biosciences Relative Risk vs. Return Landscape
If you would invest 1,531 in MBX Biosciences Common on October 21, 2025 and sell it today you would earn a total of 2,522 from holding MBX Biosciences Common or generate 164.73% return on investment over 90 days. MBX Biosciences Common is generating 1.7538% of daily returns assuming volatility of 6.0236% on return distribution over 90 days investment horizon. In other words, 54% of stocks are less volatile than MBX, and above 65% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
MBX Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MBX Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MBX Biosciences Common, and traders can use it to determine the average amount a MBX Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2912
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | MBX | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average MBX Biosciences is performing at about 23% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MBX Biosciences by adding it to a well-diversified portfolio.
MBX Biosciences Fundamentals Growth
MBX Stock prices reflect investors' perceptions of the future prospects and financial health of MBX Biosciences, and MBX Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MBX Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | 1.43 B | ||||
| Shares Outstanding | 44.9 M | ||||
| Price To Book | 4.70 X | ||||
| EBITDA | (67.95 M) | ||||
| Net Income | (61.92 M) | ||||
| Total Debt | 171 K | ||||
| Book Value Per Share | 8.67 X | ||||
| Cash Flow From Operations | (54.68 M) | ||||
| Earnings Per Share | 7.67 X | ||||
| Market Capitalization | 1.82 B | ||||
| Total Asset | 268.54 M | ||||
| Retained Earnings | (137.5 M) | ||||
| Working Capital | 256.24 M | ||||
About MBX Biosciences Performance
Evaluating MBX Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MBX Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MBX Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.28) | (0.26) |
Things to note about MBX Biosciences Common performance evaluation
Checking the ongoing alerts about MBX Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MBX Biosciences Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MBX Biosciences is way too risky over 90 days horizon | |
| MBX Biosciences appears to be risky and price may revert if volatility continues | |
| Reported Net Loss for the year was (61.92 M) with profit before taxes, overhead, and interest of 0. | |
| MBX Biosciences generates negative cash flow from operations | |
| MBX Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is UBSs Canvuparatide Focus Altering The Investment Case For MBX Biosciences |
- Analyzing MBX Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MBX Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining MBX Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MBX Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MBX Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MBX Biosciences' stock. These opinions can provide insight into MBX Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MBX Stock Analysis
When running MBX Biosciences' price analysis, check to measure MBX Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences is operating at the current time. Most of MBX Biosciences' value examination focuses on studying past and present price action to predict the probability of MBX Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences' price. Additionally, you may evaluate how the addition of MBX Biosciences to your portfolios can decrease your overall portfolio volatility.